Kentucky is currently home to 1063 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Louisville, Lexington, Owensboro and Paducah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
NCT06967389
Recruiting
The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are: * How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment? * How do risk markers of disease change over the study in the study participant... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
07/01/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Obesity and Overweight, Obese Adolescents, Weight Management, Weight Loss, Cardiovascular Disease Risk Factor
Register for Updates
Description of Patients With Type 1 Diabetes Treated With Teplizumab
NCT06892002
Recruiting
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of β cell autoimmunity and thus presence of islet autoantibodies, without the presence of dysglycemia and symptoms. Stage 2 T1D includes the presence of islet autoantibodies and dysglycemia, also with no symptoms. Stage 3 T1D includes presence of islet autoantibodies, overt hyperglycemia, and symptoms... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/01/2025
Locations: University of Louisville, Louisville, Kentucky
Conditions: Type 1 Diabetes
Register for Updates
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Fort Mitchell, Kentucky
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
ROSE-Longitudinal Assessment With Neuroimaging
NCT05089331
Recruiting
The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE study of cases with deep and lobar intracerebral hemorrhage to perform advanced neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function at baseline, 6 months after baseline, and 12 months after baseline to determine predictors of recovery, progressive cognitive or functional impairment. The investigators propose to leverage the recruitment, DNA, RNA-seq and baseline advanced neu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Baptist Health Louisville, Louisville, Kentucky
Conditions: Intracerebral Hemorrhage
Register for Updates
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399
Recruiting
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occu... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/01/2025
Locations: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Register for Updates
Genetic and Environmental Risk Factors for Hemorrhagic Stroke
NCT00682695
Recruiting
The purpose of this study is to find risk factors for hemorrhagic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Baptist Health Louisville, Louisville, Kentucky
Conditions: Stroke
Register for Updates
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
NCT06750185
Recruiting
This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Norton Cancer Institute PARENT, Louisville, Kentucky
Conditions: Advanced Solid Tumor
Register for Updates
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626
Recruiting
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main quest... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Norton Cancer Institute, Louisville, Kentucky
Conditions: Metastatic Breast Cancer
Register for Updates
Pain and Activity Levels After Orthodontic Separators
NCT05615688
Recruiting
The primary aim of this study is to evaluate the reported pain intensity following placement of Orthodontic separators on healthy volunteers aged 15-49 in relation to their recorded physical activity level. Hypothesis 1: The investigators hypothesize that participants with higher daily step counts and physical activity levels will report significantly less pain intensity from orthodontic separators than their less active peers following separator placement. Null hypothesis is that participants... Read More
Gender:
ALL
Ages:
Between 15 years and 49 years
Trial Updated:
06/30/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Dental Malocclusion
Register for Updates
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955
Recruiting
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio ≤150) due to pneumonia or other infections. Potential subjects hospitalized with pneumonia or other infections are to be screened within 24 hours of diagnosis of ARDS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2025
Locations: University of Louisville Hospital - Jewish Hospital, Louisville, Kentucky
Conditions: Acute Respiratory Distress Syndrome, Infections
Register for Updates
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449
Recruiting
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: L-MARC Research Center, Louisville, Kentucky
Conditions: Obesity
Register for Updates
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: University of Kentucky Medical Center, Lexington, Kentucky
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates